Verastem, Inc.

VSTM

US92337C2035

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:54:28 2024-04-19 am EDT			5-day change	1st Jan Change
9.965 ^USD	-2.59%		-11.30%	+23.14%

Apr. 18	Verastem Names John Hayslip as Chief Medical Officer	MT
Apr. 18	Verastem Oncology Announces Executive Changes	CI

Verastem: Q3 Earnings Snapshot

November 04, 2021 at 05:30 pm EDT

NEEDHAM, Mass. (AP) _ Verastem Inc. (VSTM) on Thursday reported a loss of $22.8 million in its third quarter.

On a per-share basis, the Needham, Massachusetts-based company said it had a loss of 13 cents.

The drug developer posted revenue of $2,000 in the period.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VSTM at https://www.zacks.com/ap/VSTM

Latest news about Verastem, Inc.

Verastem Names John Hayslip as Chief Medical Officer	Apr. 18	MT
Verastem Oncology Announces Executive Changes	Apr. 18	CI
Verastem, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Verastem, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Verastem Oncology's Ovarian Cancer Drug Gets FDA Orphan Drug Designation	Mar. 05	DJ
Verastem Gets Orphan Drug Designation From US FDA for Avutometinib to Treat Type of Ovarian Cancer	Mar. 05	MT
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers	Jan. 29	CI
Sector Update: Health Care Stocks Mixed Premarket Friday	Jan. 19	MT
Sector Update: Health Care	Jan. 19	MT
Verastem Gets Fast Track Label For Avutometinib Combination in Non-Small Cell Lung Cancer	Jan. 18	MT
Verastem Gets FDA Fast-Track Approval on Lung Cancer Treatment	Jan. 18	DJ
Verastem Oncology Selects Oral Kras G12d Inhibitor Gfh375/Vs-7375 as Lead Program in Discovery and Development Collaboration with Genfleet Therapeutics	Dec. 18	CI
Verastem Starts Confirmatory Trial of Ovarian Cancer Treatment Candidate	Dec. 13	MT
Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer	Dec. 13	CI
Truist Securities Cuts Price Target on Verastem to $34 From $39, Maintains Buy Rating	Nov. 15	MT
Verastem Oncology Announces the Launch of the New Healthcare Professional Component	Nov. 13	CI
Verastem, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Verastem Promotes Vice President of Finance Dan Calkins to CFO	23-10-27	MT
Verastem Oncology Promotes Dan Calkins to Chief Financial Officer	23-10-26	CI
Verastem Oncology Announces Executive Appointments	23-10-26	CI
Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS? in KRAS G12C-Mutant Non-Small Cell Lung Cancer	23-10-14	CI
B. Riley Starts Verastem at Buy With $21 PT, Notes Likely Accelerated Approval of Avutometinib + defactinib for Low-Grade Serous Ovarian Cancer	23-09-27	MT
Certain 5.00% Convertible Senior Notes due 2048. of Verastem, Inc. are subject to a Lock-Up Agreement Ending on 14-SEP-2023.	23-09-13	CI
Certain Series B Preferred Stock of Verastem, Inc. are subject to a Lock-Up Agreement Ending on 14-SEP-2023.	23-09-13	CI
Certain Series A Preferred Stock of Verastem, Inc. are subject to a Lock-Up Agreement Ending on 14-SEP-2023.	23-09-13	CI

Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Companyâs advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), and melanoma. Avutometinib is an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma (RAS)/RAF/MEK, ERK mitogen activated pathway kinase (MAPK) pathway. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2).

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.23 USD

Average target price

28.79 USD

Spread / Average Target

+181.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERASTEM, INC.	+23.14%	259M
VERTEX PHARMACEUTICALS INCORPORATED	-3.11%	102B
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.78%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-28.04%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.15%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.46%	10.94B

Bio Therapeutic Drugs

Verastem, Inc.

Equities

VSTM

US92337C2035

Biotechnology & Medical Research

Verastem: Q3 Earnings Snapshot

Latest news about Verastem, Inc.

Chart Verastem, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs